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Improved prenatal diagnosis of the congenital nephrotic syndrome of
the Finnish type based on DNA analysis. Haplotype analysis and a-feto-
protein quantitation comprise a prenatal diagnosis of congenital nephro-
sis. Congenital nephrotic syndrome of the Finnish type (CNF) is an
autosomal recessive disease characterized by massive proteinuria and
nephrotic syndrome from birth. Prenatal diagnosis of CNF has previously
been based on the quantitation of a-fetoprotein (AFP) in the amniotic
fluid and maternal serum, hut an increased AFP is not specific for the
disease. We have recently localized the CNF gene to the chromosome
19q13.1 region and observed a strong linkage disequilibrium to the genetic
markers D19S610, D19S608, D19S224 and D19S220 in this chromosomal
area. Four main CNF-haplotypes have been observed in Finnish kindreds.
In the present study, linkage and haplotype analyses have been applied to
prenatal diagnosis of six families with a history of CNF. The results
diminish the risk of false positive diagnosis and abortions of healthy
fetuses in families at risk.
Congenital nephrotic syndrome of the Finnish type (CNF,
NPHS1, MIM 256 300) is inherited in an autosomal recessive
manner [1]. Characteristic to CNF is massive proteinuria starting
already in utero, a large placenta (over 25% of the child's birth
weight) and nephrotic syndrome from birth [1, 21, and the
incidence of CNF in Finland is 12.2 in 100,000 newborns [3].
Previously, all CNF patients died usually within the first year of
life, but during the last decade CNF patients have been treated
successfully with early intravenous albumin supplementation,
nutritional support, aggressive treatment of complications and
early renal transplantation after nephreclomy and dialysis [4, 5].
CNF can be reliably detected prenatally during the second
trimester by elevated a-fetoprotein (AFP) levels in the amniotic
fluid [6]. However, AFP values can be elevated also in other fetal
abnormalities, mostly structural anomalies such as neural tube
defects and abdominal wall defects. CNF is, especially in Finland,
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a likely cause for very high amniotic fluid AFP in pregnancies
where ultrasound shows no fetal abnormalities.
We have localized the CNF gene to the chromosome 19q13.1
region by linkage analysis [7, 8]. The critical region is flanked by
genetic markers D19S208 and D19S224, with a genetic distance of
approximately 3 cM. A significant linkage disequilibrium has been
found with several genetic markers, D19S610, D19S608, D19S224
and D19S220 on this chromosomal region [7, 8], and the markers
with a significant association allowed us to construct four main
haplotypes observed in Finnish kindreds comprising 90% of all
observed CNF haplotypes. Using the haplotype analysis, we have
been able to perform first trimester prenatal diagnosis by chori-
onic villus sampling in families with a known risk for CNF.
Haplotype analysis can also be beneficial in cases with elevated
amniotic fluid AFP without a family history of CNF. In the
present study we have used this approach to carry out prenatal
diagnoses in three Finnish families with an affected child, and in
three families where the first pregnancy was terminated because
of highly elevated AFP values in the amniotic fluid and, as
subsequent renal histology revealed, typical CNF findings. In
addition to these, we have analyzed the correlation between the
CNF haplotype and the quantitated AFP from the maternal
serum or the amniotic fluid in 18 cases.
Methods
Pedigrees and DNA samples
The families in this study consisted of three Finnish families
with a child affected with CNF and three Finnish families where a
pregnancy had been terminated on the basis of high AFP levels in
the amniotic fluid (Figs. 1 and 2). The diagnosis of CNF in index
cases was based on massive proteinuria, a large placenta, mani-
festation of nephrotic syndrome soon after birth, exclusion of
other types of congenital ncphrotic syndrome and typical findings
in renal histology [9]. Haplotype analysis was also performed for
eight families in which an elevation of amniotic fluid AFP raised
a suspicion of CNF. Altogether in 18 cases in these families, AFP
values were quantitated in the maternal serum or in the amniotic
fluid (Table 1). Nine of the fetuses (cases no. 1, 2, 4, 5, 6, 9, 10, 12,
14 in Table 1) were aborted based on elevated AFP values in the
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amniotic fluid, and DNA samples were sent to us for haplotype
analysis for CNF. Histological findings of the kidney specimen
were consistent with CNF in all cases except for case no. 14, and
electron microscopic studies were performed in cases no. 1, 4, 9,
10 and 12 (Table 1) supporting the diagnosis of CNF. Seven
prenatal diagnoses were performed on the basis of high AFP
values in the maternal serum and the amniotic fluid or on the basis
of the family CNF histoiy (cases no. 3, 7, 13, 15, 16, 17, 18). Cases
no. 8 and 11 in Table I are the healthy siblings of family no. 7 (Fig.
1) presented in this article.
Genomic DNA from whole EDTA-blood samples was isolated
in an automated DNA extractor (Applied Biosystems Inc., 340A).
For prenatal diagnosis DNA from a chorion villus sample was
isolated by standard procedures [10].
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Fig. 1. Pedigrees and results of the prenatal diagnosis in families with a CNF affected child. Observed CNF haplotypes with genetic markers D19S610,
D19S608, D19S224 and D19S220 are shown in bold. Abbreviations are: f, father; m, mother; c, child. Symbols are: (:) pregnancy; (•) aborted fetus.
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Fetus
(Family no.)a Haplotype
Am-AFP
jrg/liter
Gestation
week
Affection
status
1. (51)
2.
6-2-x-9/6-2-x-9
6-2-x-9/6-2-x-9
83,000
328,000
476,800
17—18
20
17—18
A(EM)
A
3 (44)b 6-2-x-9/6-2-x-9 250,400 14—15 A(EM)
4. 6-2-x-9/6-8-x-6 265,200 16—17 A(EM)
5. 6-2-x-9/6-8-x-5 475,000 16—17 A
6. 6-2-x-9/6-8-x-4 365,200 17—18 A
7. (46)
8. (7 c3)b
6-2-8-9/4b-10-3-7
6-2-8-9/3-10-x-2
108,400
113,300
14—15
15—16
A
H/C
9. (46) 6-2-8-9/4b-10-3-7 69,500 17 A
10. (47)
11. (7 c2)"
6-2-8-9/4-10-3-6
6-2-8-9/3-10-x-2
68,900
82,500
42,800
15,600
17—18
16
18
21—22
A(EM)
H/C
12. 6-2-x-9/4b-10-x-7 59,900 16—17 A(EM)
13. 6-2-x-x/3-10-x-x 40,580
22,800
18
19
pregnancy
not yet at
term
14. 6-2-x-9/3-10-x-11 139,600
94,000
16—17
19
H
15. 6-8-9-5/2-10-2-6 70,900 16 A
16. 6-8-x-5/4-10-x-6 64,700
50,300
17
18—19
H
17. (18 c3)t' 4-10-3-9/8-9-10-7 S-AFP
11
14—15 H/C
18. (7 c5)h 6-8-10-5/7-8-10-11 S-AFP 15—16 H/C
Risk calculations
The risks of the fetuses being affected with CNF were calcu-
lated using the MLINK program of the LINKAGE package [11].
Allele frequencies were counted in the Finnish CNF families
previously used for linkage analysis [7] and for fine mapping of the
CNF locus [8], and combined with those included in the risk
calculations only. Together they consisted of 96 normal and 96
CNF chromosomes.
Markers D19S610 and D19S608 were included in the calcula-
tion, and the locus order assigned D19S610-CNF-D19S608 with
0.005 recombination fraction between the marker loci.
Analysis of genetic markers
Polymorphic CA-repeat microsatellite markers from the critical
DNA region for the CNF locus (D19S610, D19S608, D19S224,
D19S220) were analyzed by PCR amplification, followed by gel
electrophoresis. The cloning and mapping of the CA-repeat
microsatellite markers D19S610 and D19S608 have been de-
scribed by Männikko et al [8], and markers D19S224 and D19S220
were obtained from Genethon. PCR reactions were performed as
described by Kestilä et al [7] and by Männikkö et al [8].
Results
Prenatal diagnosis in families with a CNF-affected child
The refined mapping of the CNF locus has enabled more
accurate prenatal diagnosis for the disease on the basis of linkage
and haplotype analyses in families with a history of CNF. These
methods were applied for a family (no. 7, Fig. 1) with one affected
child from the first pregnancy and two healthy siblings. The CNF
haplotypes found in DNA from the affected first child in this
family were 6-2-8-9 and 7-8-10-11 with markers D19S610,
D19S608, D19S224 and D19S220, respectively, the haplotype
6-2-8-9 being the most common CNF haplotype observed in
Finnish CNF families. During the second and third pregnancies
resulting in healthy babies, AFP values in the amniotic fluid were
clearly elevated above normal reference values to 82,500 j.g/liter
and 113,300 pg/liter at gestational week 16, respectively (Table 1,
Fetus 11 and 8). However, in the case of the second pregnancy the
values decreased at gestational weeks 18 and 21 to 22 to normal
levels of 42,800 and 15,600 g/liter, respectively (Table 1, Fetus
11). During the fourth pregnancy a chorion villus sample was
taken at the 11th week of pregnancy, and markers from the CNF
gene region were analyzed. The fetus was shown to have the same
genotype as the affected deceased child, and the risk of being
affected was calculated to be 99.8%. AFP quantitation at the 16th
week of pregnancy was also offered to the parents, but they wished
to terminate the pregnancy immediately (12th week of gestation),
when the results of the DNA diagnosis became known, and
histological analysis was therefore not performed. Another hap-
lotype analysis was made later for the same family in the fifth
pregnancy. This fetus was shown to have inherited the same
chromosomal area from the father as the affected child, but a
different chromosome from the mother, indicating that the fetus
was a healthy carrier, which was also the result of the risk
calculations with the probability of 99.7% (Table 2). Maternal
serum AFP level was normal (34 pg/liter, gestational week 15—16,
Table 1, Fetus 18), and the child was born healthy.
Prenatal diagnosis was also performed for two other families,
each with one affected child born (families no. 18 and 44, Fig. 1).
In family no. 18 the CNF-haplotypes were 6-2-8-9 and 4-10-3-9,
that probably originates from haplotype 3-10-3-x. They are both
among the four main haplotype categories observed in Finnish
CNF families (Table 3). Interestingly, the non-CNF haplotype of
the mother in this family is 6-2-10-, with a part of the most
common CNF haplotype [6-2-8-9]. Reliable diagnosis could still
be performed based on the CNF history of the family and because
the family had a healthy sibling with this haplotype from the
mother. The prenatal diagnosis showed that the fetus had inher-
ited the CNF haplotype 4-10-3-9 from the mother, but a different
haplotype than the affected child from the father, indicating with
a 99.9% probability that the fetus would be a healthy carrier. The
APP value in maternal serum was normal (11 jig/liter, gestational
week 14—15, Table 1, Fetus 17). The child was born healthy.
In family no. 44 the analyzed fetus had inherited CNF-haplo-
type 6-2-x-9 from both parents, which is also the genotype of the
affected child in that family, and the risk for the fetus being
affected was calculated to be 99.4%. The AFP values in the
amniotic fluid were typically high for CNF (250,400 j.tg/liter,
gestational week 14—15, Table 1, Fetus 3), and the pregnancy was
therefore terminated, Electron microscopic findings of the renal
biopsy were consistent with CNF.
Table 1. All CNF haplotype analyses performed for fetuses, with
elevated aipha-fetoprotein (AFP) values: haplotypes with markers
D19S610, D19S608, D19S224, D19S220 and AFP levels in the amniotic
fluid (Am-AFP) or in the maternal serum (S-AFP)
34
Affection status is indicated as: H, healthy; A, affected (based on
histological and/or electron microscopic studies, EM); C, carrier based on
haplotype analysis in families with CNF history. The reference values for
Am-AFP vary depending on the gestation week (gw) ranging from
<41,000 jig/liter (gw 14) to < 25,000 jig/liter (gw 20) (see [181 for details).
S-AFP reference values for gw 14-15 are < 44 jig/liter.a Families are numbered as in Fig. 1 and Fig. 2b CNF-child previously born in this family. Haplotype in CNF chromo-
some is marked with bold letters.
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Table 2. Risks of fetuses being affected, unaffected carriers, or non-carriers in families with a CNF history
Family 7
fetus 1
Family 7
fetus 2
Family
18
Family
44
Family 46
fetus 2
Family 47
fetus 2
Family 51
fetus 2
Affected 99.8% 0.3% 0% 99.4% 99.4% 0% 0%
Nonaffected 0.3% 99.7% 99.9% 0.6% 0.6% 99.9% 99.9%
carrier
Noncarrier 0% 0% 0% 0% 0% 0% 0%
Table 3. Four main CNF haplotype categories observed in Finnish
CNF families
Haplotype
(D19S610, D19S608, D19S224,
D19S220)
-
% of chromosomes
CNF non-CNF
6-2-8-9 56 1
6-6-4-x 13 0
6-8-10-x 12 4
3-10-3-x 7 1
Others 11 93
Total 99 99
Haplotypes that share a part of the CNF haplotype are also included in
the categories. A more detailed table is presented by Männikkö et al
(1995).
Analysis of suspected CNF cases without CNF histoty
In a family without a previous CNF history (no. 46, Fig. 2) the
first pregnancy was previously terminated because of elevated
AFP values (69,500 rg/liter, Table 1, Fetus 9) during the 17th
week of gestation. Renal histology and electron microscopic
findings were typical for CNF as described in studies of Autio-
Harmainen [12]. Markers from the CNF chromosomal region
were analyzed in this family to obtain information for future
pregnancies, and also to determine the CNF haplotypes of the
parents and the CNF fetus. From the mother the fetus had
inherited the most common haplotype in the Finnish population,
that is, 6-2-8-9 for markers D19S610, D19S608, D19S224 and
Dl 9S220, respectively, and from the father the haplotype 4b-10-
3-7 originating probably from haplotype 3-10-3-x, which is one of
the four main haplotype categories observed in Finnish CNF
kindreds. In the second pregnancy the fetus had inherited the
same genotype as the first fetus, the calculated risk being 99.4%.
In this pregnancy the amniotic fluid AFP value was again above
normal reference values (108,400 jLg!liter, gestational week 15,
Table 1, Fetus 7). The parents chose termination of the preg-
nancy, and the electron microscopic findings supported the diag-
nosis of CNF.
Similar analyses were performed for two other families (no. 47
and 51, Fig. 2). In both families the first pregnancy had been
terminated because of elevated AFPvalues in the amniotic fluid
(family no, 47, 68,900 jig/liter, gestational week 17—18, Fetus 10 in
Table 1; and family no. 51, 83,000 jig/liter, gestational week 17—18,
and 328,000 jig/liter, gestational week 20, Fetus 1 in Table 1).
Histological and electron microscopic findings from the fetal
kidney were typical for CNF in both cases. Haplotype analysis
revealed common CNF haplotypes: in family no. 47 haplotypes
4-10--6 and 6-2-8-9, and in family no. 51 haplotypes 6-2-8-9 from
both parents. In the second pregnancy the fetus in family no. 47
had inherited the CNF haplotype 4-10-x-6 from the mother, but
the non-CNF haplotype from the father, thus being a carrier. The
AFP values were not studied, because the chromosome analysis
revealed 21-trisomy and the pregnancy was terminated. The fetus
in the second pregnancy of the family no. 51 was also shown to be
a carrier with a CNF haplotype 6-2-x-9 from the father and
non-CNF haplotype from the mother. AFP values were not
studied and the child was born healthy.
Haplolype analyses in non-CNF families
Haplotype analyses were performed in nine pregnancies (Table
1, Fetus no. 2, 4, 5, 6, 12, 13, 14, 15, 16), in which an elevated
maternal serum AFP had been found in maternal serum trisorny
screening program. The amniotic fluid AFP was consequently also
found to be elevated, thus causing a suspicion of CNF in the
absence of any ultrasound signs for fetal abnormalities.
Correlation between CNF haplotypes and AFP-quantitation
The correlation between the analyzed CNF-haplotypes and
quantitated AFP values of the amniotic fluid was studied in 18
cases (Table 1). In cases no. 1 to 3 with CNF haplotype 6-2-x-9
homozygote (with markers D19S610, D19S608, D19S224,
D19S220), the AFP in the amniotic fluid was extremely high
(> 250,000 jig/liter). A highly elevated amniotic fluid AFP was
also found in cases no. 4 to 6 with a heterozygote CNF haplotype
6-2-8-9/6-8-x-4. In all of these cases the histological or electron
microscopical studies revealed findings typical for CNF. When in
a heterozygote CNF haplotype there was the most common
haplotype 6-2-x-9 from one parent and the haplotype 3-10-x (or its
derivates 4-10-3-x/4b-10-3-x) from another parent, the AFP values
were elevated to 40,000 to 110,000 jig/liter (case no. 7 to 14, Table
1). These cases include both aborted fetuses, where histological
findings were consistent with CNF, and pregnancies that resulted
in healthy babies.
Normal AFP values were measured for case no. 17, which was
a prenatal diagnosis performed for family no. 18, child 3 (present-
ed in this article, Fig. 1), and haplotype analysis indicated the fetus
to be a healthy carrier. Normal AFP values were also measured in
case no. 18, the second prenatal diagnosis for family no. 7, child 5
(Fig. 1), the fetus being a carrier of the CNF haplotype 7-8-10-11.
Interestingly, the haplotype in non-CNF chromosome was 6-8-
10-5, which is observed in 12% of CNF chromosomes analyzed in
Finnish families (Table 3).
Discussion
The refined localization of the CNF gene and the strong linkage
disequilibrium observed with the genetic markers in the CNF
gene region (19q13.1) in Finnish CNF families has facilitated
prenatal diagnosis with high accuracy in families with a CNF
history. Prenatal diagnosis employing linkage disequilibrium has
previously been succesfully utilized in some other diseases en-
riched in the Finnish population in pre-mutation detection era,
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like diastrophic dysplasia [13], infantile ceroid lipofuscinosis [141,
cartilage-hair hypoplasia [15] and the Salla disease [16].
CNF has previously been diagnosed prenatally in Finland based
on highly elevated levels of AFP in the amniotic fluid. This
analysis is usually accomplished after the 15th week of gestation.
However, increased AFP levels are not specific for CNF and it is
difficult to determine diagnostic levels for the disease. This is
problematic especially in families with no CNF history. Our study
gives evidence (family no. 7, Table 1) that in the case of an
unaffected carrier fetus there may be an initial rise in amniotic
fluid AFP, which may be considered diagnostic for CNF leading to
termination of the pregnancy, when a decrease to normal levels
can occur later during the pregnancy. It seems possible that even
when histopathological changes typical for CNF in the fetal
kidneys have been confirmed, the aborted fetus in fact could have
been unaffected at birth.
In families with no previous CNF history the observed linkage
disequilibrium in the CNF gene region can now be used to identify
the four major haplotypes with a coverage of 90% of the CNF
alleles in Finland. There seems to be a correlation between the
CNF haplotype and highly elevated AFP in the amniotic fluid.
The two most common haplotypes, 6-2-x-9 and 6-8-x-y, in homozy-
gote and heterozygote states were observed in all cases where
AFP values were highly elevated ranging them to 250,000 to
500,000 /.Lglliter. These haplotypes are thought to represent one
ancestral mutation [8] and the data presented here support that
hypothesis. When these haplotypes existed with some other
haplotype, the AFP values were also elevated above normal
values. A decrease in the amount of AFP in the amniotic fluid was
observed when quantitation was repeated in three cases, raising a
question of whether a carrier with the most common CNF
haplotype has signs of nephrotic syndrome at certain developmen-
tal stages. Thus, in cases where CNF is suspected based on
elevated AFP to levels 60,000 to 100,000 tg/liter, the quantitation
should be repeated to confirm CNF with increased values and to
exclude the possibility of a carrier case.
In families with a history of CNF DNA-based prenatal diagno-
sis can be performed during the first trimester. As shown in the
present study the CNF diagnosis can be done with up to a 95%
accuracy, taking into consideration the small possibility of double
recombination between the markers. However, a positive inter-
ference is observed in chromosome 19 [17], meaning that a double
recombination is unlikely to occur.
In the future, cloning of the CNF gene and identification of the
mutation(s) causing the disease will replace the haplotype analysis
in prenatal diagnosis and make reliable carrier screening possible
even at the general population level.
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